Ivosidenib in combinational therapy (intensive or low intensive chemotherapy) is currently being studied in randomized phase III trials investigating previously untreated AML patients with an IDH1 mutation (NCT03839771 and NCT03173248). Here, IDH1 is linked to acute myeloid leukemia.